Vial, a US-based startup that offers clinical trial services to biotechnology companies, has raised $67 million in a Series B funding round led by General Catalyst. The funding round also saw participation from Byers Capital and BoxGroup, among others. The startup, co-founded by Simon Burns and Andrew Brackin, has so far raised more than $100 million.